سعر جاستروبيوتيك 550مجم 30 قرص 2024

Rifaximin 550 mg film-coated tablets, 30 per pack (3 strips), by Andalous Pharma.

• Reduction in risk of overt hepatic encephalopathy recurrence.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of irritable bowel syndrome with diarrhea (IBS-D).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Travelers diarrhea trials: headache was the most common adverse reaction (about 10% vs 9% with placebo). Postmarketing: hypersensitivity reactions (including exfoliative dermatitis, angioedema, anaphylaxis), C. difficile colitis; rhabdomyolysis has been reported in patients with cirrhosis; severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any component of the tablet.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Not effective in diarrhea complicated by fever and/or blood in the stool or caused by pathogens other than E. coli; discontinue if diarrhea worsens or persists more than 24-48 hours. Clostridioides difficile-associated diarrhea has been reported. To reduce drug-resistant bacteria, use only for infections proven or strongly suspected to be caused by bacteria. Use with caution in severe hepatic impairment and with P-glycoprotein inhibitors such as cyclosporine.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• P-glycoprotein inhibitors (e.g. cyclosporine)Concomitant P-gp inhibitors can substantially increase systemic rifaximin exposure; use caution, especially in hepatic impairment.DailyMed (U.S. National Library of Medicine)
• WarfarinChanges in INR have been reported with rifaximin and warfarin; monitor INR and prothrombin time and adjust warfarin as needed.DailyMed (U.S. National Library of Medicine)

• No available human data on use in pregnancy; rifaximin was teratogenic in rats and rabbits at clinically relevant exposures, and may cause fetal harm. Advise pregnant women of the potential risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No information on the presence of rifaximin in human milk or effects on the breastfed infant or milk production; weigh breastfeeding benefits against the need for the drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Rifaximin: Semi-synthetic rifampin derivative that binds the beta-subunit of bacterial DNA-dependent RNA polymerase, blocking transcription and inhibiting bacterial growth (US label).